Crossmark

Adjuvant recombinant human endostatin combined with toripalimab (anti-PD-1) in locally advanced melanoma: an exploratory phase 2 clinical trial incorporating single-cell RNA/TCR/BCR sequencing

Crossref DOI link: https://doi.org/10.1186/s12943-026-02675-w

Published Online: 2026-04-27

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Hu, Xianglin

Xu, Yu

Wang, Zixin

Yang, Lingge

Zheng, Biqiang

Sun, Feifan

Liu, Dongsong

Shi, Bochong

Zheng, Haoyu

Liu, Xin

Yu, Lin

Zhang, Shengjian

Yan, Yan

Yan, Wangjun

Sun, Yangbai

Chen, Yong

Wang, Chunmeng
License Information

Text and Data Mining valid from 2026-04-27

Version of Record valid from 2026-06-11
More Information

Article History

Received: 10 December 2025

Accepted: 21 April 2026

First Online: 27 April 2026

Declarations

:

: This research was approved by the ethics committee of Fudan University Shanghai Cancer Center, Shanghai, China.

: All authors read and approved the submission.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below